Market Cap: $12.09B
AI
Arrowhead Pharmaceuticals, Inc.
ARWR
NASDAQ (NASDAQ Global Select)USD
Market Cap: $12.09B
Arrowhead Pharmaceuticals (Ticker: ARWR) is making significant strides in the development of treatments for serious metabolic and genetic diseases. During recent discussions, Chief Medical Officer Jam…
Arrowhead Pharmaceuticals (Ticker: ARWR) recently emphasizes its commitment to advancing siRNA therapeutics, highlighted by key developments shared during a recent Jefferies fireside chat. Chief Medic…
Arrowhead Pharmaceuticals (Ticker: ARWR) announces an exclusive licensing agreement with Madrigal Pharmaceuticals for the development of a therapeutic targeting metabolic dysfunction-associated steato…
Arrowhead Pharmaceuticals (Ticker: ARWR) is at a pivotal moment as it transitions into a commercial phase while focusing on expanding its RNA interference pipeline. At the recent BofA Annual Healthcar…
Arrowhead Pharmaceuticals (ARWR) experiences a significant breakthrough as the Australian Therapeutic Goods Administration grants approval for its innovative drug, REDEMPLO (plozasiran). This latest d…
Arrowhead Pharmaceuticals Advances Gene Editing Innovations Arrowhead Pharmaceuticals is at the forefront of revolutionizing medical treatment through its innovative approaches in RNA-targeted therape…
Arrowhead Pharmaceuticals Makes Strides in Obesity Treatment with Promising Clinical Trial Results Arrowhead Pharmaceuticals is making significant advancements in the field of obesity treatment, as in…
Arrowhead Pharmaceuticals Navigates Market Challenges Amid Broader Economic Concerns Arrowhead Pharmaceuticals faces a complex economic landscape as market downturns continue to shape investor sentime…
Arrowhead Pharmaceuticals: A Surge in Performance Reflecting Strong Strategic Execution Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) reveals a significant uptick in its stock value following the rel…
Advancements in Genetic Medicine: A New Chapter for Rare Disease Therapies The recent FDA approval for dosing in Cohort 8 of the ENDEAVOR study conducted by Sarepta Therapeutics Inc. significantly hig…
Arrowhead Pharmaceuticals Advances in Genetic Medicine Landscape Arrowhead Pharmaceuticals, Inc. is making significant strides in the field of genetic medicine, positioning itself as a key player in t…
Arrowhead Pharmaceuticals Focuses on Advancing RNAi-Based Therapeutics Amid Upcoming Earnings Announcement As Arrowhead Pharmaceuticals prepares to announce its quarterly earnings on November 25, 2025…
Arrowhead Pharmaceuticals Advances RNAi-Based Therapeutics Amid Promising Pipeline Developments Arrowhead Pharmaceuticals focuses on the advancement of its innovative RNA interference (RNAi) therapeut…
Arrowhead Pharmaceuticals Secures FDA Approval for Redemplo, a Breakthrough Treatment for Familial Chylomicronemia Syndrome Arrowhead Pharmaceuticals, Inc. announces a major milestone as the U.S. Food…
Arrowhead Pharmaceuticals Breaks New Ground with Redemplo Approval for Familial Chylomicronemia Syndrome Arrowhead Pharmaceuticals, Inc. has achieved a significant milestone with the U.S. Food and Dru…
CRISPR Therapeutics Advances Gene Editing with CTX310 Trial Data In a significant development within the biotechnology sector, CRISPR Therapeutics AG (NASDAQ:CRSP) presents promising Phase 1 data from…
Biotechnology Sector Shows Promising Momentum Recent developments in the biotechnology sector highlight the remarkable advancements in research and innovation that are driving investor confidence and…
Arrowhead Pharmaceuticals: Riding the Wave of Biotechnology Momentum Arrowhead Pharmaceuticals finds itself at a significant juncture within the biotechnology sector, as recent developments highlight…
Arrowhead Pharmaceuticals Navigates Economic Headwinds While Advancing Pipeline Arrowhead Pharmaceuticals, a leader in RNA-targeted therapies, continues to focus on its innovative drug development des…
Arrowhead Pharmaceuticals Navigates the Genetic Therapy Landscape Amidst Industry Developments In the biotechnology sector, advancements in gene therapies are forging new pathways for treatment option…
### Regulatory Setback for Innovative DMD Treatment Arrowhead Pharmaceuticals faces a significant challenge this week as the Committee for Medicinal Products for Human Use (CHMP) of the European Medic…
Arrowhead Pharmaceuticals: Focus on Innovative Therapeutics Amidst Market Optimism Arrowhead Pharmaceuticals continues to carve a niche for itself in the biopharmaceutical industry with its innovative…
Arrowhead Pharmaceuticals: Advancing Targeted Therapies Amid Market Optimism Arrowhead Pharmaceuticals is at the forefront of developing innovative therapies that target specific genetic diseases. The…
Arrowhead Pharmaceuticals Faces Industry Headwinds Amid Biotech Challenges Arrowhead Pharmaceuticals experiences a significant downturn in its stock price, mirroring broader difficulties faced by the…
Arrowhead Pharmaceuticals Faces Challenges Amid Industry Turbulence Arrowhead Pharmaceuticals, a prominent player in the biotechnology sector, experiences a turbulent trading day as it faces significa…
Arrowhead Pharmaceuticals: Navigating Financial Viability Amid Industry Scrutiny Arrowhead Pharmaceuticals faces increasing scrutiny regarding its financial viability, raising questions about its futu…
Arrowhead Pharmaceuticals: Advancing RNA Therapeutics Amid Market Turbulence Arrowhead Pharmaceuticals continues to make significant strides in the field of RNA therapeutics, focusing on innovative tr…
Arrowhead Pharmaceuticals and Sarepta Therapeutics Forge Groundbreaking Collaboration Arrowhead Pharmaceuticals, Inc. solidifies a significant partnership with Sarepta Therapeutics, finalizing a globa…
Arrowhead Pharmaceuticals Advances Familial Chylomicronemia Syndrome Treatment with FDA NDA Acceptance Arrowhead Pharmaceuticals, Inc. has made a significant stride in the development of plozasiran, a…
Arrowhead Pharmaceuticals Advances Plozasiran for Familial Chylomicronemia Syndrome Arrowhead Pharmaceuticals, Inc. announces a significant milestone with the U.S. Food and Drug Administration's (FDA)…
Arrowhead Pharmaceuticals Expands Workforce with Strategic Inducement Grants Arrowhead Pharmaceuticals, Inc. announces the approval of inducement grants aimed at strengthening its workforce as part of…
Arrowhead Pharmaceuticals Advances RNA Therapeutic for Complement-Mediated Diseases Arrowhead Pharmaceuticals, Inc. announces positive interim findings from its Phase 1/2a clinical trial of ARO-CFB, a…
Arrowhead Pharmaceuticals Advances ARO-CFB in Complement-Mediated Disease Treatment Arrowhead Pharmaceuticals, Inc. unveils compelling interim results from its Phase 1/2a clinical study of ARO-CFB, an…
Arrowhead Pharmaceuticals Showcases RNAi Innovations at Upcoming Conferences Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is set to highlight its advancements in RNA interference (RNAi) therapeutics…
Arrowhead Pharmaceuticals Advances Therapeutic Development with Strategic Initiatives Arrowhead Pharmaceuticals, Inc. is making significant strides in the biopharmaceutical industry, particularly with…
Arrowhead Pharmaceuticals Partners with Sarepta Therapeutics to Expand Rare Disease Pipeline Arrowhead Pharmaceuticals, a pioneer in RNA interference (RNAi) therapies, recently enters a transformative…
Arrowhead Pharmaceuticals and Sarepta Therapeutics Forge Strategic Partnership in Genetic Medicine Arrowhead Pharmaceuticals, Inc. has entered into a transformative global licensing and collaboration…
Arrowhead Pharmaceuticals Advances Innovative Treatment for Familial Chylomicronemia Syndrome Arrowhead Pharmaceuticals, Inc. has reached a pivotal moment in its development pipeline by submitting a N…
Arrowhead Pharmaceuticals Prepares for Key Events in November 2024 Arrowhead Pharmaceuticals, Inc. is set to make significant contributions to the field of gene therapy and RNA interference during a s…
Arrowhead Pharmaceuticals Launches Awareness Campaign for Rare Disease FCS Arrowhead Pharmaceuticals, Inc. has taken a significant step in supporting the rare disease community by launching the 'We'll…